Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

NCT01668667 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

501

Enrollment

INDUSTRY

Sponsor class

Conditions

Restless Legs Syndrome

Interventions

DRUG: GSK1838262 600 mg
DRUG: GSK1838262 450 mg
DRUG: GSK1838262 300 mg
DRUG: GSK1838262 Placebo match

Sponsor

XenoPort, Inc.